METHOD OF TREATING PATIENTS WITH REPERFUSION SYNDROME Russian patent published in 2023 - IPC A61K31/702 A61K31/351 A61K31/616 A61K31/5375 A61K31/4365 A61K31/727 A61K35/16 A61K31/4415 A61K31/51 A61K31/714 A61P43/00 

FIELD: medicine.

SUBSTANCE: invention relates to a method of treating patients with reperfusion syndrome after reconstructive surgical interventions on the arteries of the lower extremities. The method is as follows: the treatment is carried out in three stages: at the first stage of treatment lasting 10 days, the following medicinal products are used: Longidaza 3,000 IU, it is dissolved in 1.0–2.0 ml of 0.5% Novocaine solution and injected in the first interdigital space once, Phlebodia 600 mg 2 tablets in the morning orally, Clopidogrel 75 mg per day, ThromboAss 100 mg per day, Rivaroxaban 2.5 mg 2 times a day orally, Sulodexide 600 LE intravenous drip and Actovegin 10 ml intravenous drip, Neuromultivit 2 ml intramuscularly once a day, class 2 elastic compression of the lower extremities — elastic stockings, individually selected in size and elevated position of the limb on a splint. At the second stage of treatment lasting 10 days, elastic compression of the lower extremities of class 2 is still used, and the following medicinal products are used: ThromboAss 100 mg per day, Clopidogrel 75 mg 1 tablet once a day, Rivaroxaban 2.5 mg 1 tablet 2 times a day, Phlebodia 600 mg 1 tablet 1 time a day in the morning, Sulodexide 600 LE intramuscularly once a day, Neuromultivit 1 tablet 3 times a day, Actovegin 5 ml intramuscularly 1 time a day. At the third stage, elastic compression of the lower extremities of class 2 is still used, and the following disaggregants are used: ThromboAss 100 mg 1 tablet once a day, Clopidogrel 75 mg 1 tablet once a day, Rivaroxaban 2.5 mg 1 tablet 2 times a day for 12 months, Phlebodia 600 mg 1 tablet once a day in the morning for 3 months, Sulodexide 250 LE 1 capsule 2 times a day orally for 2 months, Neuromultivitis 1 tablet 3 times a day orally for 1 month, Actovegin 2 capsules 3 times a day orally for 4 months.

EFFECT: invention provides a reduction or complete absence of reperfusion edema of the operated lower limb, and a reduction of treatment time.

1 cl, 2 ex